Literature DB >> 2229133

D-19466, a new cyclobutane-platinum complex with antitumor activity.

R Voegeli1, W Schumacher, J Engel, J Respondek, P Hilgard.   

Abstract

D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It had excellent anticancer activity in vivo against a number of murine experimental tumors, including a cisplatin-resistant P388 line. Clinical evaluation of this compound has therefore been initiated.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2229133     DOI： 10.1007/bf01612990

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  4 in total

Review 1.  Carboplatin: current status and future prospects.

Authors:  R Canetta; K Bragman; L Smaldone; M Rozencweig
Journal:  Cancer Treat Rev       Date:  1988-06       Impact factor: 12.111

2.  The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity.

Authors:  M Iselt; W Holtei; P Hilgard
Journal:  Arzneimittelforschung       Date:  1989-07

3.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

4.  Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).

Authors:  M van Glabbeke; J Renard; H M Pinedo; F Cavalli; J Vermorken; C Sessa; R Abele; M Clavel; S Monfardini
Journal:  Eur J Cancer Clin Oncol       Date:  1988-02
  4 in total
  6 in total

1.  A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer.

Authors:  M Degardin; J P Armand; B Chevallier; P Cappelaere; M A Lentz; M David; H Roché
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 2.  Nanocarriers for delivery of platinum anticancer drugs.

Authors:  Hardeep S Oberoi; Natalia V Nukolova; Alexander V Kabanov; Tatiana K Bronich
Journal:  Adv Drug Deliv Rev       Date:  2013-10-08       Impact factor: 15.470

3.  Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.

Authors:  R C Rietbroek; P J van de Vaart; J Haveman; F A Blommaert; A Geerdink; P J Bakker; C H Veenhof
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions.

Authors:  H J Guchelaar; D R Uges; P Aulenbacher; E G de Vries; N H Mulder
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Lobaplatin-Induced Apoptosis Requires p53-Mediated p38MAPK Activation Through ROS Generation in Non-Small-Cell Lung Cancer.

Authors:  Hongming Zhang; Runzhe Chen; Xiyong Wang; Haijun Zhang; Xiaoli Zhu; Jibei Chen
Journal:  Front Oncol       Date:  2019-07-24       Impact factor: 6.244

Review 6.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review.

Authors:  H Timmer-Bosscha; N H Mulder; E G de Vries
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.